- Home
- TRIP vs TSHA Comparison
TRIP vs TSHA Comparison
Compare TRIP & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRIP | TSHA |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TRIP | TSHA |
|---|---|---|
| Price | $10.87 | $6.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $14.58 | $11.11 |
| AVG Volume (30 Days) | ★ 3.7M | 2.7M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | 5.56 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $1,556,000,000.00 | $9,773,000.00 |
| Revenue This Year | $3.33 | N/A |
| Revenue Next Year | $5.12 | $1,152.42 |
| P/E Ratio | $35.42 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $9.01 | $1.70 |
| 52 Week High | $20.16 | $6.70 |
Technical Indicators
Market Signals| Indicator | TRIP | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 49.71 | 67.34 |
| Support Level | $9.36 | $4.39 |
| Resistance Level | $11.08 | N/A |
| Average True Range (ATR) | 0.50 | 0.42 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 17.62 | 83.30 |
Price Performance
Historical ComparisonAbout TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2025, 42% of revenue came from the company's core Hotel and Other segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2025, and TheFork, its dining brand, represented 12% of sales.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.